These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21577013)

  • 1. Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles.
    Bauerschlag DO; Ammerpohl O; Bräutigam K; Schem C; Lin Q; Weigel MT; Hilpert F; Arnold N; Maass N; Meinhold-Heerlein I; Wagner W
    Oncology; 2011; 80(1-2):12-20. PubMed ID: 21577013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers.
    Wei SH; Chen CM; Strathdee G; Harnsomburana J; Shyu CR; Rahmatpanah F; Shi H; Ng SW; Yan PS; Nephew KP; Brown R; Huang TH
    Clin Cancer Res; 2002 Jul; 8(7):2246-52. PubMed ID: 12114427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization.
    Ahluwalia A; Yan P; Hurteau JA; Bigsby RM; Jung SH; Huang TH; Nephew KP
    Gynecol Oncol; 2001 Aug; 82(2):261-8. PubMed ID: 11531277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression.
    Keita M; Wang ZQ; Pelletier JF; Bachvarova M; Plante M; Gregoire J; Renaud MC; Mes-Masson AM; Paquet ÉR; Bachvarov D
    Gynecol Oncol; 2013 Feb; 128(2):356-63. PubMed ID: 23219462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy.
    Strathdee G; Vass JK; Oien KA; Siddiqui N; Curto-Garcia J; Brown R
    Gynecol Oncol; 2005 Jun; 97(3):898-903. PubMed ID: 15894365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
    Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment.
    Barton CA; Hacker NF; Clark SJ; O'Brien PM
    Gynecol Oncol; 2008 Apr; 109(1):129-39. PubMed ID: 18234305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis.
    Lu L; Katsaros D; de la Longrais IA; Sochirca O; Yu H
    Cancer Res; 2007 Nov; 67(21):10117-22. PubMed ID: 17974952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling of epithelial ovarian tumours correlated with malignant potential.
    Warrenfeltz S; Pavlik S; Datta S; Kraemer ET; Benigno B; McDonald JF
    Mol Cancer; 2004 Oct; 3():27. PubMed ID: 15471544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer.
    Katsaros D; Cho W; Singal R; Fracchioli S; Rigault De La Longrais IA; Arisio R; Massobrio M; Smith M; Zheng W; Glass J; Yu H
    Gynecol Oncol; 2004 Sep; 94(3):685-92. PubMed ID: 15350359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
    Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
    Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma.
    Friedrich MG; Chandrasoma S; Siegmund KD; Weisenberger DJ; Cheng JC; Toma MI; Huland H; Jones PA; Liang G
    Eur J Cancer; 2005 Nov; 41(17):2769-78. PubMed ID: 16242928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic DNA methylation biomarkers in ovarian cancer.
    Wei SH; Balch C; Paik HH; Kim YS; Baldwin RL; Liyanarachchi S; Li L; Wang Z; Wan JC; Davuluri RV; Karlan BY; Gifford G; Brown R; Kim S; Huang TH; Nephew KP
    Clin Cancer Res; 2006 May; 12(9):2788-94. PubMed ID: 16675572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer.
    Kaneuchi M; Sasaki M; Tanaka Y; Shiina H; Verma M; Ebina Y; Nomura E; Yamamoto R; Sakuragi N; Dahiya R
    Biochem Biophys Res Commun; 2004 Apr; 316(4):1156-62. PubMed ID: 15044106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer.
    Frigola J; Solé X; Paz MF; Moreno V; Esteller M; Capellà G; Peinado MA
    Hum Mol Genet; 2005 Jan; 14(2):319-26. PubMed ID: 15574462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer.
    Czekierdowski A; Czekierdowska S; Wielgos M; Smolen A; Kaminski P; Kotarski J
    Neuro Endocrinol Lett; 2006 Jun; 27(3):381-6. PubMed ID: 16816827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.
    Goodheart MJ; Ritchie JM; Rose SL; Fruehauf JP; De Young BR; Buller RE
    Clin Cancer Res; 2005 May; 11(10):3733-42. PubMed ID: 15897570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
    Kim EJ; Kim YJ; Jeong P; Ha YS; Bae SC; Kim WJ
    J Urol; 2008 Sep; 180(3):1141-5. PubMed ID: 18639281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.